An updated systematic review of the impact of medications with anticholinergic activity on cognitive function and mortality

Ian Maidment, Wei-Yee Chan, Nelson Bua, Phyo Myint, Noll Campbell, Malaz Boustani, Chun Shing Kwok, Chris Fox

Research output: Contribution to journalAbstract

Abstract

An estimated 18% of older (≥ 65) adults suffer from mild cognitive impairment (MCI). More than half will progress to dementia within 5 years. Primary prevention may be by recognition of the true burden of anticholinergic drugs on cognition and avoidance wherever possible. This project aimed to systematically review the literature to update a widely used scale that assesses anti-cholinergic burden (ACB scale) and establish the impact of drugs with anticholinergic properties on cognitive function in patients over the age of 18 without a diagnosis of dementia.
Original languageEnglish
Pages (from-to)P774
Number of pages1
JournalAlzheimer's and Dementia
Volume9
Issue number4
DOIs
Publication statusPublished - 2013

Fingerprint

Cholinergic Antagonists
Cognition
Dementia
Mortality
Primary Prevention
Pharmaceutical Preparations

Cite this

An updated systematic review of the impact of medications with anticholinergic activity on cognitive function and mortality. / Maidment, Ian; Chan, Wei-Yee; Bua, Nelson; Myint, Phyo; Campbell, Noll; Boustani, Malaz; Kwok, Chun Shing; Fox, Chris.

In: Alzheimer's and Dementia, Vol. 9, No. 4, 2013, p. P774.

Research output: Contribution to journalAbstract

Maidment, Ian ; Chan, Wei-Yee ; Bua, Nelson ; Myint, Phyo ; Campbell, Noll ; Boustani, Malaz ; Kwok, Chun Shing ; Fox, Chris. / An updated systematic review of the impact of medications with anticholinergic activity on cognitive function and mortality. In: Alzheimer's and Dementia. 2013 ; Vol. 9, No. 4. pp. P774.
@article{3cbd998551a04ac8912a9c5ea802008e,
title = "An updated systematic review of the impact of medications with anticholinergic activity on cognitive function and mortality",
abstract = "An estimated 18{\%} of older (≥ 65) adults suffer from mild cognitive impairment (MCI). More than half will progress to dementia within 5 years. Primary prevention may be by recognition of the true burden of anticholinergic drugs on cognition and avoidance wherever possible. This project aimed to systematically review the literature to update a widely used scale that assesses anti-cholinergic burden (ACB scale) and establish the impact of drugs with anticholinergic properties on cognitive function in patients over the age of 18 without a diagnosis of dementia.",
author = "Ian Maidment and Wei-Yee Chan and Nelson Bua and Phyo Myint and Noll Campbell and Malaz Boustani and Kwok, {Chun Shing} and Chris Fox",
year = "2013",
doi = "10.1016/j.jalz.2013.05.1578",
language = "English",
volume = "9",
pages = "P774",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - An updated systematic review of the impact of medications with anticholinergic activity on cognitive function and mortality

AU - Maidment, Ian

AU - Chan, Wei-Yee

AU - Bua, Nelson

AU - Myint, Phyo

AU - Campbell, Noll

AU - Boustani, Malaz

AU - Kwok, Chun Shing

AU - Fox, Chris

PY - 2013

Y1 - 2013

N2 - An estimated 18% of older (≥ 65) adults suffer from mild cognitive impairment (MCI). More than half will progress to dementia within 5 years. Primary prevention may be by recognition of the true burden of anticholinergic drugs on cognition and avoidance wherever possible. This project aimed to systematically review the literature to update a widely used scale that assesses anti-cholinergic burden (ACB scale) and establish the impact of drugs with anticholinergic properties on cognitive function in patients over the age of 18 without a diagnosis of dementia.

AB - An estimated 18% of older (≥ 65) adults suffer from mild cognitive impairment (MCI). More than half will progress to dementia within 5 years. Primary prevention may be by recognition of the true burden of anticholinergic drugs on cognition and avoidance wherever possible. This project aimed to systematically review the literature to update a widely used scale that assesses anti-cholinergic burden (ACB scale) and establish the impact of drugs with anticholinergic properties on cognitive function in patients over the age of 18 without a diagnosis of dementia.

U2 - 10.1016/j.jalz.2013.05.1578

DO - 10.1016/j.jalz.2013.05.1578

M3 - Abstract

VL - 9

SP - P774

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 4

ER -